Stem Cell Research Products and Services
- Embryonic Stem Cells (ESCs)
- Hematopoietic Stem Cells (HSCs)
- Mesenchymal Stem Cells (MSCs)
- Multipotent Adult Progenitor Stem Cells
- Induced Pluripotent Stem Cells (iPSCs)
- Neural Stem Cells (NSCs)
Cell Therapy is the transplantation of new, healthy cells into a patient's body to regenerate, replace and repair damaged cells and tissues. Stem cells are unspecialized cells capable of self-renewal and can differentiate into more mature cells with specialized functions. They have received great medical interest as a new treatment option and spurred a new age in regenerative medicine.
Esco Aster has leveraged on the Tide Motion bioreactors to establish a robust and scalable platform using macrocarriers to meet the demands for future clinical therapies.
We present our services and process optimization with quality controls and release criteria of functional and phenotypic characteristics for the translation of academic/industrial R&D into bench scale for future clinical trials and commercialization process.
An optimised bioprocess pipeline will provide for maximum yield and quality at the cost of minimum consumables. Both secreted products and cells for use in cell therapy benefit greatly from process optimisation. Optimisation performed at small scale is a perfect complement to linearly scalable bioreactors, avoiding large costs incurred when optimising in large volumes.
Having extensive 2D and 3D expansion platform experience, including our in-house BioNOC II® carriers in Tide Motion® bioreactors:
Frozen stem cells can be kept for extended periods of time and can still exercise their regenerative abilities upon recovery. When combined with stem cell isolation from tissue:
Our proprietary in-house Tide Motion® bioreactors, with the capability to house packed bed volumes ranging from as low as 0.1 L to 200 L, provides an excellent platform for the expansion of stem cells. Together with our process optimization services and cell banking services, we provide a one stop solution for all stem cells or stem cell-derived product production needs:
For MSCs to be classified as such, they are required to fulfill several criteria as specified by ISCT:
A wide variety of reagents are used in the bioprocessing of MSCs. Such chemicals include trypsinisation enzymes, various media formulations (serum-containing/free media) and serum sources (FBS/HPL), surface coatings (fibronection, gelatin, laminin, collagen etc) and more.
Part and parcel of process optimisation, our MSC team is experienced in assessing the efficacy of MSC reagents, including identifying potentially lasting cell damage from chemical exposure.
MSCs can be isolated from a wide range of tissue sources to be harnessed for regenerative therapy. Our isolated MSCs allow for faster expansion and greater total expansion numbers due to being younger as compared to other commercial sources as we do not over-expand our cells. We expand cells based on population doubling with characterization to ensure its quality.
